Gilead’s twice-yearly injectable PrEP, Yeztugo was recently approved by the FDA, but the story doesn’t end there. In this episode of The Biotech Brief, we explore how Gilead is leveraging global partnerships, generics, and regulatory streamlining to deliver Yeztugo to low- and middle-income countries without delay. Building on Episode 1, “Changing the Game in HIV Prevention,” this follow-up digs into what equitable access really takes and what drug developers can learn from it.

Folgen-ID: 1000716867877

GUID: theheii.podbean.com/2f13760d-7693-358e-8e0c-da8e2de93e64

Erscheinungs­datum: 11.7.2025, 20:11:32